Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

References

• Girard MP, Cherian T, Pervikov Y, Kieny MP. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005; 23:5708 - 24; http://dx.doi.org/10.1016/j.vaccine.2005.07.046; PMID: 16154667
   PubMed Web of Science ®Google Scholar
• Thompson MG. Estimates of Deaths Associated with Seasonal Influenza-United States, 1976-2007. Morb Mortal Wkly Rep 2010; 59:1057 - 62
   PubMedGoogle Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086 - 96; http://dx.doi.org/10.1016/j.vaccine.2007.03.046; PMID: 17544181
   PubMed Web of Science ®Google Scholar
• Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012; 486:420 - 8; PMID: 22722205
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879 - 85; http://dx.doi.org/10.1093/infdis/jir661; PMID: 21998477
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36 - 44; http://dx.doi.org/10.1016/S1473-3099(11)70295-X; PMID: 22032844
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, et al, US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951 - 9; http://dx.doi.org/10.1093/cid/cis574; PMID: 22843783
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165 - 74; http://dx.doi.org/10.1016/S0140-6736(05)67339-4; PMID: 16198765
   PubMed Web of Science ®Google Scholar
• Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165:265 - 72; http://dx.doi.org/10.1001/archinte.165.3.265; PMID: 15710788
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172 - 80; http://dx.doi.org/10.1086/599790; PMID: 19508159
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650 - 8; http://dx.doi.org/10.1086/590434; PMID: 18652550
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505 - 17; http://dx.doi.org/10.1038/nrmicro1681; PMID: 17558426
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8:45 - 58; PMID: 22251994
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492 - 503; http://dx.doi.org/10.1016/j.immuni.2010.10.002; PMID: 21029960
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant--‘the long and winding road’. Drug Discov Today 2009; 14:541 - 51; http://dx.doi.org/10.1016/j.drudis.2009.02.009; PMID: 19508916
   PubMed Web of Science ®Google Scholar
• Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733 - 44; http://dx.doi.org/10.1093/infdis/jir641; PMID: 22315336
   PubMed Web of Science ®Google Scholar
• Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012; 206:811 - 20; http://dx.doi.org/10.1093/infdis/jis427; PMID: 22782949
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406 - 16; http://dx.doi.org/10.1056/NEJMoa1010331; PMID: 21995388
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23:Suppl 1 S10 - 25; http://dx.doi.org/10.1016/j.vaccine.2005.04.019; PMID: 15908062
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46:1078 - 84; http://dx.doi.org/10.1086/529197; PMID: 18444828
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343 - 51; http://dx.doi.org/10.1056/NEJMoa055778; PMID: 16571878
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010; 28:Suppl 3 C25 - 36; http://dx.doi.org/10.1016/j.vaccine.2010.07.021; PMID: 20713254
   PubMed Web of Science ®Google Scholar
• Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036 - 44; http://dx.doi.org/10.1056/NEJMra1002842; PMID: 21083388
   PubMed Web of Science ®Google Scholar
• Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8:607 - 18; http://dx.doi.org/10.1586/erv.09.19; PMID: 19397417
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960 - 8; http://dx.doi.org/10.1016/S0264-410X(97)00301-0; PMID: 9682344
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, et al. Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand 1999; 98:101 - 10, discussion 111; PMID: 10494963
   PubMedGoogle Scholar
• Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001; 19:1911 - 23; http://dx.doi.org/10.1016/S0264-410X(00)00445-X; PMID: 11228361
   PubMed Web of Science ®Google Scholar
• Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 2010; 7:1433 - 46; http://dx.doi.org/10.1517/17425247.2010.538047; PMID: 21118032
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565 - 72; http://dx.doi.org/10.1016/j.vaccine.2010.01.029; PMID: 20117262
   PubMed Web of Science ®Google Scholar
• Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, et al. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine 2009; 27:6399 - 403; http://dx.doi.org/10.1016/j.vaccine.2009.06.014; PMID: 19552895
   PubMed Web of Science ®Google Scholar
• Wright PF. Vaccine preparedness--are we ready for the next influenza pandemic?. N Engl J Med 2008; 358:2540 - 3; http://dx.doi.org/10.1056/NEJMp0803650; PMID: 18550873
   PubMed Web of Science ®Google Scholar
• Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 2010; 12:21 - 30; PMID: 20140813
   PubMed Web of Science ®Google Scholar
• Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751 - 9; http://dx.doi.org/10.1016/S0140-6736(10)62228-3; PMID: 21329971
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012; 30:4377 - 86; http://dx.doi.org/10.1016/j.vaccine.2011.11.114; PMID: 22172502
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012; 54:946 - 54; http://dx.doi.org/10.1093/cid/cir959; PMID: 22267715
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573 - 84; http://dx.doi.org/10.1056/NEJMoa073121; PMID: 18550874
   PubMed Web of Science ®Google Scholar
• Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, et al. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377 - 89; http://dx.doi.org/10.1016/j.vaccine.2011.02.090; PMID: 21397719
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science 2012; 336:1531 - 3; http://dx.doi.org/10.1126/science.1221466; PMID: 22723412
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol 2007; 7:484 - 90; http://dx.doi.org/10.1016/j.coph.2007.06.004; PMID: 17644429
   PubMed Web of Science ®Google Scholar
• Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11:349 - 66; http://dx.doi.org/10.1586/erv.11.192; PMID: 22380826
   PubMed Web of Science ®Google Scholar
• Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642 - 9; http://dx.doi.org/10.1086/590913; PMID: 18576945
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699 - 710; http://dx.doi.org/10.1586/14760584.6.5.699; PMID: 17931151
   PubMed Web of Science ®Google Scholar
• Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7:e33536; http://dx.doi.org/10.1371/journal.pone.0033536; PMID: 22470453
   PubMed Web of Science ®Google Scholar
• Barnier Quer C, Elsharkawy A, Romeijn S, Kros A, Jiskoot W. Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone. Eur J Pharm Biopharm 2012; 81:294 - 302; http://dx.doi.org/10.1016/j.ejpb.2012.03.013; PMID: 22487055
   PubMed Web of Science ®Google Scholar
• Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 2010; 28:6527 - 41; http://dx.doi.org/10.1016/j.vaccine.2010.04.011; PMID: 20412874
   PubMed Web of Science ®Google Scholar
• Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrøm T, Enouf V, van der Werf S, et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011; 29:6283 - 91; http://dx.doi.org/10.1016/j.vaccine.2011.06.040; PMID: 21722683
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008; 26:552 - 61; http://dx.doi.org/10.1016/j.vaccine.2007.11.054; PMID: 18162266
   PubMed Web of Science ®Google Scholar
• Mahnke YD, Saqr A, Hazenfeld S, Brady RC, Roederer M, Subbramanian RA. Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses. Vaccine 2011; 29:8606 - 14; http://dx.doi.org/10.1016/j.vaccine.2011.09.019; PMID: 21939709
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333 - 9; PMID: 16670345
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158 - 66; http://dx.doi.org/10.1093/infdis/jis330; PMID: 22551811
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274 - 80; http://dx.doi.org/10.1038/nm.2612; PMID: 22286307
   PubMed Web of Science ®Google Scholar
• Doukas J, Morrow J, Bellinger D, Hilgert T, Martin T, Jones D, et al. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. Vaccine 2011; 29:5443 - 52; http://dx.doi.org/10.1016/j.vaccine.2011.05.060; PMID: 21641955
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Luke TC, Doukas J, Danko J, Porter K, Burgess T, et al. A dengue DNA vaccine formulated with Vaxfectin (®) is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum Vaccin Immunother 2012; 8:8; PMID: 23032166
   PubMed Web of Science ®Google Scholar
• Shlapobersky M, Wei Q, Sullivan S, Vilalta A. Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters. Vaccine 2009; 27:6404 - 10; http://dx.doi.org/10.1016/j.vaccine.2009.06.087; PMID: 19607952
   PubMed Web of Science ®Google Scholar
• Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028 - 36; http://dx.doi.org/10.1016/j.vaccine.2007.05.013; PMID: 17614165
   PubMed Web of Science ®Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008; 389:569 - 77; http://dx.doi.org/10.1515/BC.2008.060; PMID: 18953724
   PubMed Web of Science ®Google Scholar
• Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237 - 47; http://dx.doi.org/10.1016/S0092-1157(77)80008-5; PMID: 408355
   PubMedGoogle Scholar
• Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91 - 5; http://dx.doi.org/10.1016/j.virusres.2004.02.019; PMID: 15163495
   PubMed Web of Science ®Google Scholar